The current combined evidence from conventional and from network meta-analyses of randomised controlled trial (RCT) data is that menopausal hormone therapy (MHT) is effective for the relief of vasomotor symptoms. We noted this in our editorial and agree with the National Institute for Health and Care Excellence (NICE) guidelines on this matter, so we are unsure why Sarri and colleagues considered this a point of contention.